OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance
OptimizeRx Corporation (OPRX)
NASDAQ:AMEX Investor Relations:
optimizerx.com/investors
Company Research
Source: GlobeNewswire
- Q3 revenue of $26.1 million, increased 22% year-over-year- Q3 gross profit increased 30% year-over-year to $17.5 million- Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million- Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million- Paid off an incremental $2 million in principal from term loan subsequent to the end of Q3 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended September 30, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the third quarter of 2025 increased 22% to $26.1 million,
Show less
Read more
Impact Snapshot
Event Time:
OPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPRX alerts
High impacting OptimizeRx Corporation news events
Weekly update
A roundup of the hottest topics
OPRX
News
- How Recent Developments Are Shaping the OptimizeRx Investment Story [Yahoo! Finance]Yahoo! Finance
- OptimizeRx (NASDAQ:OPRX) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- OptimizeRx (NASDAQ:OPRX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- OptimizeRx (NASDAQ:OPRX) had its price target lowered by analysts at Stephens from $20.00 to $17.00. They now have an "equal weight" rating on the stock.MarketBeat
- OptimizeRx (OPRX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
OPRX
Earnings
- 11/6/25 - Beat
OPRX
Sec Filings
- 11/10/25 - Form 4
- 11/10/25 - Form 3
- 11/7/25 - Form 4
- OPRX's page on the SEC website